^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunomodulator

    Related drugs:
    16h
    Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=47, Completed, Beijing Friendship Hospital | Not yet recruiting --> Completed | N=26 --> 47 | Trial completion date: Mar 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Tevimbra (tislelizumab-jsgr) • Zadaxin (thymalfasin)
    16h
    CHILURSO: Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis (clinicaltrials.gov)
    P2, N=94, Not yet recruiting, University Hospital, Montpellier | Trial completion date: Aug 2028 --> Aug 2029 | Initiation date: Feb 2026 --> Dec 2026 | Trial primary completion date: Sep 2027 --> Sep 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    19h
    Liensinine induces autophagy and apoptosis in hepatocellular carcinoma via reactive oxygen species-mediated inhibition of the PI3K/AKT/mTOR pathway. (PubMed, Tissue Cell)
    Lien exerts anti-HCC effects by promoting autophagy and apoptosis through ROS-mediated inhibition of the PI3K/AKT/mTOR pathway.
    Journal
    |
    BECN1 (Beclin 1)
    |
    hydroxychloroquine
    1d
    MSB-DR004: Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov)
    P3, N=300, Active, not recruiting, Mesoblast, Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Jul 2028 | Trial primary completion date: Oct 2026 --> Jul 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    1d
    Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous (clinicaltrials.gov)
    P3, N=6, Completed, Centre Hospitalier Universitaire de Nice | Unknown status --> Completed
    Trial completion
    3d
    ALLERDOG SWEDE: Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice (clinicaltrials.gov)
    P4, N=40, Recruiting, Karolinska Institutet
    New P4 trial
    3d
    FILAXOS: A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=489, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=700 --> 489
    Enrollment closed • Enrollment change
    3d
    Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients (clinicaltrials.gov)
    P3, N=308, Recruiting, Materia Medica Holding
    New P3 trial
    4d
    Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. (PubMed, Cancer Res)
    Therapeutic Tα-1 supplementation produced strong synergy with chemotherapy to control established tumors in mice with high miR146a-5p expression in a TLR7-dependent manner. These findings establish Tα-1 as a pivotal endogenous microRNA chaperone that unlocks a critical limiting step of DC licensing, empowering robust antitumor immunity after chemotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TLR7 (Toll Like Receptor 7)
    |
    Zadaxin (thymalfasin)
    4d
    IQUALYSEP: Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=144, Completed, Rennes University Hospital | Unknown status --> Completed | N=250 --> 144
    Trial completion • Enrollment change • HEOR
    |
    mitoxantrone • Tysabri (natalizumab)
    7d
    ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=55, Completed, Orionis Biosciences Inc | Active, not recruiting --> Completed
    Trial completion
    |
    ORB-011
    8d
    L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction (clinicaltrials.gov)
    P4, N=133, Recruiting, Beni-Suef University
    New P4 trial